Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Deals Strategy Generic Drugs

Upsher-Smith Shuffles Portfolio With A Pair Of Deals

Expands Partnership With Appco As Two ‘Dormant’ ANDAs Are Divested

  • News

Executive Summary

Sawai’s Upsher-Smith business in the US has announced a pair of deals that will see the firm expand an existing partnership with Appco for a “near-term generic product opportunity” as well as divesting two “dormant” ANDAs in favor of a focus on more immediate assets.

You may also be interested in...



Deal Watch: GSK Gets Rights To Spero’s Phase III Antibiotic

GSK takes equity stake in Spero, and global rights to tebipenem except for certain Asian markets. Merck KGaA gets rights to Nerviano’s next-generation PARP inhibitor for cancer.

Asia Deal Watch: Dong-A Brings In NeuroBo As Partner On Pair Of Cardiometabolic Candidates

Plus deals involving Takeda/Puma, SillaJen/Basilea, Celltrion/Abpro, METiS/Voronoi, Yuhan/AtoGen, Biocytogen/FineImmune and Avance/C3.

Sawai Soars To New Heights In US But Flounders In Domestic Market

While Sawai’s dominant Japanese business appeared under some strain as the firm started its 2022 financial year, the company appears confident that it is still on track to meet its annual forecast.

Table

View full table

Topics

Related Companies

Tags:
Deals Strategy Generic Drugs
Latest Headlines

‘In A Word, Complicated’ – AAM’s Burton Talks US Biosimilars

ATOM Coalition Seeks Partners To Create New Oncology Markets

Dr Reddy’s Can Still Go It Alone After Penning Orencia Biosimilar Deal

Waverley Weighs Its Options With High Costs, Thin Margins

See All
UsernamePublicRestriction

Register

GB152157

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By